financetom
Business
financetom
/
Business
/
US Defense Firms Poised for Solid Q3 as Government Spending, Contracts Drive Rally, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Defense Firms Poised for Solid Q3 as Government Spending, Contracts Drive Rally, RBC Says
Oct 7, 2025 8:48 AM

11:24 AM EDT, 10/07/2025 (MT Newswires) -- The major US defense companies are expected to report solid Q3 results reflecting steady growth, contract momentum, and supportive government spending, RBC Capital Markets said in a note Monday.

Analysts, including Ken Herbert, said that these companies have seen their stock prices rise by about 30% year-to-date, with most of that growth occurring since spring. The rally appears to be driven by investor optimism around the details of the One Big Beautiful Bill and roughly $150 billion in supplemental defense funding, as well as easing concerns about the Department of Government Efficiency.

Lockheed Martin ( LMT ) , Northrop Grumman ( NOC ) , and RTX (RTX) will report results on Oct. 21, followed by General Dynamics ( GD ) on Oct. 24 and L3Harris ( LHX ) on Oct. 30, according to the note.

Growth is expected to accelerate in H2 2025, with Q3 consensus estimates averaging around 7%. Among the group, General Dynamics ( GD ) likely has the lowest hurdle to clear this quarter, while H2 setup looks especially strong for RTX, the analysts said, adding that the budget environment remains supportive, with no major impact expected from the government shutdown.

Some cautious commentary on the Golden Dome program is expected, and delays and efforts to boost competition, which could benefit defense tech firms, may weigh slightly on sentiment. "For defense prime exposure, we continue to favor Northrop Grumman ( NOC ) and RTX, and in particular see the H2 2025 RTX set-up as favorable."

The analysts raised General Dynamics' ( GD ) price target from $330 to $360; L3Harris ( LHX ) from $280 to $315; Lockheed Martin ( LMT ) from $440 to $525; Northrop Grumman ( NOC ) from $650 to $675; and RTX from $170 to $200. Stock ratings were unchanged.

Price: 344.10, Change: -2.40, Percent Change: -0.69

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
May 6, 2024
May 6 (Reuters) - Gossamer Bio ( GOSS ) said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions. Gossamer is to receive $160 million development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as...
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
May 6, 2024
07:42 AM EDT, 05/06/2024 (MT Newswires) -- Xeris Biopharma Holdings ( XERS ) said Monday it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon product. Under the agreement, Beta Bionics will utilize Xeris' XeriSol technology on its bi-hormonal pump and pump systems for people with diabetes. Xeris...
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
May 6, 2024
KKR & Co. Inc. ( KKR )  announced the signing of definitive agreements to acquire Healthium Medtech Ltd. from an affiliate of Funds advised by Apax Partners LLP. Financial details were not disclosed. Based in India, Healthium is a medical devices company that develops, manufactures, and sells a broad range of surgical products worldwide. Akshay Tanna, Partner and Head of India Private Equity at KKR, said: “Under the...
Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer
Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer
May 6, 2024
07:42 AM EDT, 05/06/2024 (MT Newswires) -- Pfizer ( PFE ) said Monday it appointed Andrew Baum as chief strategy and innovation officer, effective June 3. The company said Baum joins the company from Citi where he was head of global healthcare and managing director of equity research. Baum succeeds Aamir Malik, who recently became Pfizer's ( PFE ) chief...
Copyright 2023-2026 - www.financetom.com All Rights Reserved